Continual reassessment method for dose escalation clinical trials in oncology: a comparison of prior skeleton approaches using AZD3514 data
Crossref DOI link: https://doi.org/10.1186/s12885-016-2702-6
Published Online: 2016-08-31
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
James, Gareth D.
Symeonides, Stefan N.
Marshall, Jayne
Young, Julia
Clack, Glen
Funding for this research was provided by:
AstraZeneca (GB)
